Bisphosphonates: how do they work?

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 5, 2008, Pages 831-847

  Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

bisphosphonates; bone strength; bone turnover; fractures; pharmacodynamics; pharmacokinetics

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BINDING AFFINITY; BIOMECHANICS; BONE BIOPSY; BONE DENSITY; BONE FRAGILITY; BONE METASTASIS; BONE MINERALIZATION; BONE NECROSIS; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CALCIUM BINDING; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG BINDING SITE; DRUG CHOICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RETENTION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; DRUG URINE LEVEL; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE; HUMAN; JAW DISEASE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS;

EID: 56349158692     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.07.001     Document Type: Review

References (104)

1. Fleisch H. Bisphosphonates: mechanisms of action and clinical applications. In: Peck W.A. (Ed). Bone and mineral research annual 1 (1982), Excerpta Medica, Amsterdam 319-357
2. Blomen L.J.M.J. History of the bisphosphonates: discovery and history of the non medical uses of bisphosphonates. In: Bijvoet O.L.M., Fleisch H.A., Canfield R.E., and Russell R.G.G. (Eds). Bisphosphonates on bones (1995), Elsevier, Amsterdam 111-124
3. Benedict J.J. The physical chemistry of the diphosphonates-Its relationship to their structural activity. In: Donath A., and Courvoisier B. (Eds). Symposium CEMO IV. Nyon Switzerland (1982), Editions Medecine est Hygiene, Geneva 1-19
4. van Beek E., Hoekstra M., van de Ruit M., et al. Structural requirements for bisphosphonates actions in vitro. Journal of Bone and Mineral Research 12 (1994) 1875-1882
5. van Beek E.R., Lowik C.W.G.M., Ebetino F.H., et al. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 23 (1998) 437-442
6. Leu C.-T., Luegmayr E., Freedman L.P., et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 38 (2006) 628-636
7. Nancollas G.H., Tang R., Phipps R.J., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38 (2006) 617-627
8. Henneman Z.J., Nancollas G.H., Ebetino F.H., et al. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. Journal of Biomedical Materials Research. Part A 85 (2008) 993-1000
9. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 19 (2008) 733-759
10. van Beek, Lowik C., Que I., et al. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. Journal of Bone and Mineral Research 11 (1996) 1492-1497
11. Brown R.J., van Beek E., Watts D.J., et al. Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of the Dictyostelium discoideum. Journal of Bone and Mineral Research 13 (1998) 253-258
12. Shinoda H., Adamek G., Felix R., et al. Structure-activity relationships of various bisphosphonates. Calcified Tissue International 35 (1983) 87-99
13. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design 11 (2003) 196-214
14. Reszka A.A., and Rodan G.A. Nitrogen-containig bisphosphonate mechanism of action. Mini Reviews in Medicinal Chemistry 4 (2004) 711-719
15. Thompson K., Rogers M.J., Coxon F.P., et al. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles following fluid-phase endocytosis. Molecular Pharmacology 69 69 (2006) 1624-1632
16. Coxon F.P., Thompson K., Roelofs A.J., et al. Visualizing mineral binding and uptake of bisphosphonates by osteoclasts and non-resorbing cells. Bone 42 (2008) 848-860
17. Rogers M.J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcified Tissue International 75 (2004) 451-461
18. Coxon F.P., Thompson K., and Rogers M.J. Recent advances in understanding the mechanism of action of bisphosphonates. Current Opinion in Pharmacology 6 (2006) 307-312
19. Dunford J.E., Thompson K., Coxon F.P., et al. Structure-activity relationships for inhibition of pharnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. The Journal of Pharmacology and Experimental Therapeutics 296 (2001) 235-242
20. Monkkonen H., Auriola S., Lehenkari P., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. British Journal of Pharmacology 147 (2006) 437-445
21. Plotkin L.I., Weinstein R.S., Parfitt A.M., et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. The Journal of Clinical Investigation 104 (1999) 1363-1374
22. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
23. Plotkin L.I., Aguirre J.I., Kousteni S., et al. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. The Journal of Biological Chemistry 280 (2005) 7317-7325
24. Follet H., Li J., Phipps R.J., et al. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 40 (2007) 1172-1177
25. Plotkin L.I., Goellner J., Vyas K., et al. A bisphosphonate analog that lacks anti-remodeling activity prevents osteocyte and osteoblast apoptosis in vivo. Journal of Bone and Mineral Research 22 Suppl. 1 (2007) S4
26. Chavassieux P.M., Arlot M.E., Reda C., et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. The Journal of Clinical Investigation 100 (1997) 1475-1480
27. Bravenboer N., Papapoulos S.E., Holzman P., et al. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporosis International 9 (1999) 489-493
28. Eriksen E.F., Melsen F., Sod E., et al. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
29. Recker R.R., Weinstein R.S., Chesnut III C.H., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with post-menopausal osteoporosis: results from the BONE study. Osteoporosis International 15 (2004) 231-237
30. Recker R., Masarachia P., Santora A., et al. Trabecular bone microarchitecture after alendronate treatment of osteoporotic women. Current Medical Research and Opinion 21 (2005) 185-194
31. Recker R.R., Delmas P.D., Halse J., et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. Journal of Bone and Mineral Research 23 (2008) 6-16
32. Roschger P., Rinnerthaler S., Yates J., et al. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191
33. Boivin G.Y., Chavassieux P.M., Santora A.C., et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
34. Borah B., Ritman E.L., Dufresne T.E., et al. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone 37 (2005) 1-9
35. Borah B., Dufresne T.E., Ritman E.L., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39 (2006) 345-352
36. Roschger P., Mair G., Fratzl-Zelman N., et al. Mineralization status of bone matrix in postmenopausal women during a 10-year alendronate treatment period. Journal of Bone and Mineral Research 22 Suppl. 1 (2007) S129
37. Mashiba T., Hirano T., Turner C.H., et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. Journal of Bone and Mineral Research 15 (2000) 613-620
38. Mashiba T., Turner C.H., Hirano T., et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
39. Komatsubara S., Mori S., Mashiba T., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves trabecular bone microarchitecture in dog vertebra. Journal of Bone and Mineral Research 18 (2003) 512-520
40. Allen M.R., Iwata K., Phipps R., et al. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39 (2006) 872-879
41. Chapurlat R.D., Arlot M., Burt-Pichat B., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. Journal of Bone and Mineral Research 22 (2007) 1502-1509
42. Stepan J.J., Burr D.B., Pavo I., et al. Low bone mineral density is associated with with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41 (2007) 378-385
43. Cremers S.C.L.M., Pillai G., and Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimization of intermittent therapy for osteoporosis. Clinical Pharmacokinetics 44 (2005) 551-570
44. Cremers S.C.L.M., Papapoulos S.E., Gelderblom H., et al. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. Journal of Bone and Mineral Research 20 (2005) 1543-1547
45. Christiansen C., Phipps R., Burgio D., et al. Comparison of risedronate and alendronate pharmacokinetics at clinical doses. Osteoporosis International 14 Suppl. 7 (2003) S38
46. Rosen C.J., Hochberg M., Bonnick S., et al. Treatment with once-weekly alendronate compared to once-weekly risedronate in women with postmenopausal osteoporosis: a randomized, double-blind study. Journal of Bone and Mineral Research 20 (2005) 141-151
47. Papapoulos S.E., and Cremers S.C.L.M. Prolonged bisphosphonate release after treatment in children. The New England Journal of Medicine 356 (2007) 1075-1076
48. Khan S.A., Kanis J.A., Vasikaran S., et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. Journal of Bone and Mineral Research 12 (1997) 1700-1707
49. Cremers S., Sparidans R., den Hartigh J., et al. A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. European Journal of Clinical Pharmacology 57 (2002) 883-890
50. Bone H.G., Hosking D., Devogalaer J.-P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. The New England Journal of Medicine 350 (2004) 1189-1199
51. Hochberg M.C., Greenspan S., Wasnich R.D., et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 1586-1592
52. Bauer D.C., Black D.M., Garnero P., et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. Journal of Bone and Mineral Research 19 (2004) 1250-1258
53. Eastell R., Barton I., and Hannon R.A. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of Bone and Mineral Research 18 (2003) 1051-1056
54. Balena R., Toolan B.C., Shea M., et al. The effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in overiectomized nonhuman primates. The Journal of Clinical Investigation 92 (1993) 2577-2586
55. Lalla S., Hothorn L.A., Hag N., et al. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporosis International 8 (1998) 97-103
56. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatments with antiresorptive drugs. The American Journal of Medicine 112 (2002) 281-289
57. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 231-236
58. Hochberg M.C., Ross P.D., Black D., et al. Larger increases in bone mineral density during alendronate therapy are associated with lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis and Rheumatism 42 (1999) 1246-1254
59. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate end point. Statistics in Medicine 20 (2001) 3175-3188
60. Delmas P.D., Li Z., and Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drags: some issues with meta-analysis. Journal of Bone and Mineral Research 19 (2004) 330-337
61. Papapoulos S.E. Determinants of bone strength and clinical practice; effects of bisphosphonates. Bone 41 (2007) S3-S7
62. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
63. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA : The Journal of the American Medical Association 280 (1998) 2077-2082
64. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. The New England Journal of Medicine 333 (1995) 1437-1443
65. Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis International 9 (1999) 461-468
66. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA : The Journal of the American Medical Association 282 (1999) 1344-1352
67. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. The New England Journal of Medicine 344 (2001) 333-340
68. Reginster J.Y., Minne H.W., Sorensen O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporosis International 11 (2000) 83-91
69. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 19 (2004) 1241-1249
70. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine 356 (2007) 1809-1822
71. Lyles K.W., Colón-Emeric C.S., Magaziner J.S., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. The New England Journal of Medicine 357 (2007) nihpa40967
72. Brumsen C., Papapoulos S.E., Lips P., et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. Journal of Bone and Mineral Research. 17 (2002) 1057-1064
73. McCloskey E., Selby P., Davies M., et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. Journal of Bone and Mineral Research. 19 (2004) 728-736
74. McCloskey E.V., Beneton M., Charlesworth D., et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. Journal of Bone and Mineral Research. 22 (2007) 135-141
75. Karpf D.B., Shapiro D.R., Seeman E., et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA : The Journal of the American Medical Association 277 (1997) 1159-1164
76. Cranney A., Wells G., Willan A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews 23 (2002) 508-516
77. Cranney A., Tugwell P., Adachi J., et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews 23 (2002) 517-523
78. Papapoulos S.E., Quandt S.A., Liberman U.A., et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporosis International 16 (2005) 468-474
79. Adachi J.D., Rizzoli R., Boonen S., et al. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clinical and Experimental Research 17 (2005) 150-156
80. Boonen S., Laan R.F., Barton I.P., et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis International 16 (2005) 1291-1298
81. Wells G.A., Cranney A., Peterson J., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 1 (2008) CD001155
82. Wells G., Cranney A., Peterson J., et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 1 (2008) CD004523
83. Nguyen N.D., Eisman J.A., and Nguyen T.V. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. Journal of Bone and Mineral Research 21 (2006) 340-349
84. Cranney A., Wells G., Yetisir L., et al. Ibandronate for the prevention of non-vertebral fractures: A pooled analysis of individual patient data. Osteoporosis International, (29 July 2008) [Epub ahead of print]
85. Gasser J.A., Ingold P., and Green J. A single IV injection of equipotent doses of alendronate, risedronate, ibandronate and zoledronic acid exerts a bone protective effect of similar magnitude and duration in ovariectomized rats. Journal of Bone and Mineral Research 19 Suppl. 1 (2004) S307
86. Papapoulos S.E., and Schimmer R.C. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Annals of the Rheumatic Diseases 66 (2007) 853-858
87. McClung M.R., Wasnich R.D., Hosking D.J., et al. Early Postmenopausal Intervention Cohort Study. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 4879-4885
88. Wasnich R.D., Bagger Y.Z., Hosking D.J., et al., Early Postmenopausal Intervention Cohort Study Group. Changes in bone mineral density and turnover after alendronate or estrogen withdrawal. Menopause 11 (2004) 622-630
89. Bagger Y.Z., Tanko L.B., Alexandersen P., et al. Alendronate has a residual effect on bone mass in post-menopausal Danish women up to 7 years after treatment withdrawal. Bone 33 (2003) 301-307
90. Landman J.O., Hamdy N.A.T., Pauwels E.K.J., et al. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 3465-3468
91. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA : The Journal of the American Medical Association 296 (2006) 2927-2938
92. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporosis International 19 (2008) 365-372
93. Neele S.J.M., Evertz R., De Valk-De Roo G., et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30 (2002) 599-603
94. Schwartz A.V., Bauer D.C., Cauley J.A., et al. Efficacy of continued alendronate for fractures in women without vertebral fracture. Journal of Bone and Mineral Research 22 Suppl. 1 (2007) S16-S17
95. Mellstrom D.D., Sorensen O.H., Goemaere S., et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcified Tissue International 75 (2004) 462-468
96. Odvina C.V., Zerwekh J.E., Rao D.S., et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 1294-1301
97. Goh S.K., Yang K.Y., Koh J.S., et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. The Journal of Bone and Joint Surgery. British Volume 89 (2007) 349-353
98. Kwek E.B., Goh S.K., Koh J.S., et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?. Injury 39 (2008) 224-231
99. Lenart B.A., Lorich D.G., and Lane J.M. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. The New England Journal of Medicine 358 (2008) 1304-1305
100. Obermaier-Pietsch C.B., Marin F., McCloskey E., et al. Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: results from the Eurofors trial. Calcified Tissue International 80 Suppl. 1 (2007) s137
101. Delmas P., Watts N., Miller P., et al. Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: the OPTAMISE study. Journal of Bone and Mineral Research 22 Suppl. 1 (2007) S27
102. McClung M., Recker R., Miller P., et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41 (2007) 122-128
103. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 22 (2007) 1479-1491
104. Rizzoli R., Burlet N., Cahall D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42 (2008) 841-847